Table 1.

Effect of PKA I, PKA II, and Epac activators on LAK cell cytotoxicity

TreatmentConcentrationPKA binding siteCytotoxicity (%)
Control38.3 ± 4
CADO10 μmol/L15.0 ± 2 *
2 μmol/L21.0 ± 3 *
6-Benz-cAMP0.25 mmol/LRI A and RII A34.3 ± 6
8-PIP-cAMP0.25 mmol/LRI A and RII B35.7 ± 7
8-PIP-cAMP + 6-Benz-cAMP0.25 + 0.25 mmol/LPKA II (A + B)27.1 ± 4 *
8-HA-cAMP0.25 mmol/LRI B30.7 ± 3 *
8-HA-cAMP + 6-Benz-cAMP0.25 + 0.25 mmol/LPKA I (A + B)8.1 ± 1
8-pCPT-2′-O-Me-cAMP0.5 mmol/LEpac36.9 ± 3
8-PIP-cAMP + 6-benz-cAMP + 8-pCPT-2′-O-Me-cAMP(0.25 + 0.25) + 0.5 mmol/LPKA II + Epac23.3 ± 4 *
8-HA-cAMP + 6-benz-cAMP + 8-pCPT-2′-O-Me-cAMP(0.25 + 0.25) + 0.5 mmol/LPKA I + Epac7.8 ± 1
  • NOTE: LAK cells were incubated for 30 minutes with activators of PKA and/or Epac and then incubated for 4 hours with radiolabeled 3LL tumor cells at E/T ratio 20:1.

  • * Significantly differs from the Control group (P < 0.05).

  • Significantly differs from all other groups (P < 0.001). This experiment was repeated thrice.